Mobile Advanced Multi-Parameter Reporting in Patients Wearing a Novel Device: Utilization During Cardiac Rehabilitation (MAPS-III)

ZOLL Medical

Status: Withdrawn

Conditions: Cardiac Infarct; Cardiac Disease; NSTEMI; Heart Attack; STEMI; Cardiac Event

Treatments: Device: ZOLL Arrhythmia Management System

Study type: Observational

Funder types: Industry

Identifiers

NCT05957172

90D0257

Details and patient eligibility

About

Advanced remote multi-parameter reporting during cardiac rehabilitation (MAPS-III). The primary purpose of this observational study is to collect baseline information of cardiac rehabilitation usage in the US for post-myocardial infarction (MI) patients with EF > 35% while wearing the ZOLL AMS device for 30 to 60 days. Secondary data on biometrics, arrhythmias, symptoms, and healthcare utilization will provide additional background information on this population during the early post-MI cardiac rehabilitation period.

Full description

To collect baseline data on cardiac rehabilitation usage (referrals and completion) in recent post-MI patients with EF > 35%.To collect data on AMS-derived biometric data (e.g. HR, activity) and arrhythmias, and subject-reported symptoms, beta blocker/ivabradine usage (dose/changes) and cardiovascular events. The participating centers will enroll consenting subjects in a sequential manner to avoid preferential selection of patients to participate in the study. Subjects will be consented by the center study staff, and if eligible will wear the FDA-cleared AMS device for 30-60 days. Subject demographic information and clinical history will be obtained at the time of enrollment. During the study period, the prescribing physician-investigator will be blinded to AMS data. Final subject follow-up will be at 3 months. A sample size of 150 subjects is estimated in order to have 100 subjects with at least 30 days of AMS use for analysis.

Sex: All

Ages: 21 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

1. Both male and female subjects who are between 21 - 75 years of age, inclusively
2. Subjects who are consented and enrolled into the study prior to discharge from the qualifying acute myocardial infarction
3. Subjects with a consistent EF >35% post the qualifying acute myocardial infarction

Exclusion Criteria

1. Subjects with an implantable cardiac device such as left ventricular assistive device, pacemaker, an implanted cardioverter defibrillator (ICD), a cardiac resynchronization therapy device, subcutaneous ICDs, pressure monitors, and loop monitors.
2. Subjects with wearable cardioverter defibrillator, Holter monitors, wearable event recorders, and other mobile cardiac telemetry devices at the same time.
3. Subjects with a skin condition preventing them from wearing the AMS device.
4. Subjects who are non-ambulatory for any reason.
5. Subjects who are self-reporting to be pregnant.
6. Subjects with comorbidities that would preclude adherence to a cardiac rehabilitation program - at the discretion of the physician.
7. Subjects participating or planning to participate in another interventional study during the protocol-defined study period

Trial design

0 participants in 1 patient group

Active Treatment

Description:

Subjects assigned to wear the FDA-cleared AMS device for 30-60 days Sequential enrollment to avoid preferential selection Investigator blinded to the AMS data

Treatment:

Device: ZOLL Arrhythmia Management System